Nurix Therapeutics Inc
(NAS:NRIX)
$
15.4
-0.5 (-3.14%)
Market Cap: 940.44 Mil
Enterprise Value: 756.14 Mil
PE Ratio: 0
PB Ratio: 4.63
GF Score: 67/100 Nurix Therapeutics Inc at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) Transcript
Mar 16, 2022 / 03:00PM GMT
Release Date Price:
$13.92
(+3.57%)
Michael Schmidt
Guggenheim Securities, LLC - Senior Biotech Analyst
All right. Hello and welcome. Thanks for joining us. My name is Michael Schmidt, senior biotech analyst with Guggenheim Securities. And I'm very excited to welcome the Nurix Therapeutics team presenting today. With us today, we have our Arthur Sands, CEO; Hans van Houte, CFO; and Robert Brown, Head of Clinical. Welcome and thanks for joining us.
Arthur Sands
Nurix Therapeutics, Inc. - President, CEO and Board Director
Thank you. Thanks for having us, Michael.
Hans van Houte
Nurix Therapeutics, Inc. - CFO
Thanks, Michael.
Michael Schmidt
Guggenheim Securities, LLC - Senior Biotech Analyst
All right. I think we'll start with a brief overview, and then we'll jump into Q&A. Any investor questions, please send me an e-mail. I'll try to work those in.
Arthur Sands
Nurix Therapeutics, Inc. - President, CEO and Board Director
Thank you. So Nurix Therapeutics
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot